UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 39

Sortiert nach

Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles

Diabetes, obesity & metabolism, 2016-06, Vol.18 (6), p.558-570

2016

Volltextzugriff (PDF)

Biosimilar insulins: guidance for data interpretation by clinicians and users

Diabetes, obesity & metabolism, 2015-10, Vol.17 (10), p.911-918

2015

Volltextzugriff (PDF)

Safety, efficacy and weight effect of two 11β-HSD1 inhibitors in metformin-treated patients with type 2 diabetes

Diabetes, obesity & metabolism, 2014-11, Vol.16 (11), p.1070-1077

2014

Volltextzugriff (PDF)

Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus

Diabetes, obesity & metabolism, 2015-01, Vol.17 (1), p.82-90

2015

Volltextzugriff (PDF)

novel insulin formulation with a more rapid onset of action

Diabetologia, 2008-09, Vol.51 (9), p.1602-1606

2008

Volltextzugriff (PDF)

Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction

Diabetes, obesity & metabolism, 2011, Vol.13 (1), p.75-80

2011

Volltextzugriff (PDF)

Glucodynamics of long-acting basal insulin peglispro compared with insulin glargine at steady state in patients with type 1 diabetes: substudy of a randomized crossover trial

Diabetes, obesity & metabolism, 2016-11, Vol.18 (11), p.1065-1071

2016

Volltextzugriff (PDF)

Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin

Diabetes, obesity & metabolism, 2014-11, Vol.16 (11), p.1096-1101

2014

Volltextzugriff (PDF)

Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes

Experimental and clinical endocrinology & diabetes, 2006-09, Vol.114 (8), p.417

2006

Volltextzugriff (PDF)

Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes

European journal of endocrinology, 2010-08, Vol.163 (2), p.217

2010

Volltextzugriff (PDF)

Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus

Diabetes, obesity & metabolism, 2012-12, Vol.14 (12), p.1114-1122

2012

Volltextzugriff (PDF)

Short-term metabolic effects of prednisone administration in healthy subjects

Diabetes, obesity & metabolism, 2011-11, Vol.13 (11), p.1001-1007

2011

Volltextzugriff (PDF)

Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups

Diabetes, obesity & metabolism, 2006-09, Vol.8 (5), p.568-573

2006

Volltextzugriff (PDF)

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes

Cardiovascular diabetology, 2023-03, Vol.22 (1), p.59-59, Article 59

2023

Volltextzugriff (PDF)

Exploring the insulin secretory properties of the PGD(2)-GPR44/DP2 axis in vitro and in a randomized phase-1 trial of type 2 diabetes patients

PloS one, 2018-12, Vol.13 (12)

2018

Volltextzugriff (PDF)

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes

PloS one, 2014, Vol.9 (9), p.e110069

2014

Volltextzugriff (PDF)

Availability of Inhaled Insulin Promotes Greater Perceived Acceptance of Insulin Therapy in Patients With Type 2 Diabetes

Diabetes care, 2005-02, Vol.28 (2), p.427-428

2005

Volltextzugriff (PDF)

Evaluation of performance of a continuous glucose measurement device in subjects with type 1 and type 2 diabetes by means of a glucose clamp (hypoglycemia performance feasibility)

Canadian journal of diabetes, 2009, Vol.33 (3), p.225-225

2009

Volltextzugriff (PDF)

Safety, efficacy and weight effect of two 11[beta]-HSD1 inhibitors in metformin-treated patients with type 2 diabetes

Diabetes, obesity & metabolism, 2014-11, Vol.16 (11), p.1070

2014

Volltextzugriff (PDF)

alpha-Lipoic acid in NIDDM patients with cardiac autonomic neuropathy

Diabetes care, 1997-12, Vol.20 (12), p.1918

1997

Volltextzugriff (PDF)

Another Meaningful End Point for Nighttime Intensivist Coverage

Chest, 2015-08, Vol.148 (2), p.e66-e66

2015

Volltextzugriff (PDF)

Pharmacokinetic and Pharmacodynamic Responses of Insulin Degludec in African American, White, and Hispanic/Latino Patients With Type 2 Diabetes Mellitus

Clinical therapeutics, 2014-04, Vol.36 (4), p.507-515

2014

Volltextzugriff (PDF)

Antisense Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes

Journal of clinical lipidology, 2016-05, Vol.10 (3), p.707-708

2016

Volltextzugriff (PDF)

Rapid Glycometabolic Improvement in Type 2 Diabetic (T2D) Patients with an ADA Isocaloric Diet Over a 22-Day Confinement in a Phase I Research Unit

Journal of clinical lipidology, 2012-05, Vol.6 (3), p.277-277

2012

Volltextzugriff (PDF)

Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes

Diabetes care, 2016-08, Vol.39 (8), p.1408-1415

2016

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(35)
Buchkapitel
(4)

Sprache

Englisch
(39)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(28)
Humans
(27)
Life Sciences & Biomedicine
(25)
Endocrinology & Metabolism
(22)
Male
(21)
Female
(19)
Middle Aged
(19)
Adult
(18)
Diabetes
(15)
Diabetes Mellitus, Type 2 - Drug Therapy
(14)
Double-Blind Method
(13)
Insulin
(13)
Blood Glucose - Metabolism
(11)
Glucose Clamp Technique
(11)
Hypoglycemic Agents - Therapeutic Use
(11)
Blood Glucose - Drug Effects
(10)
Glucose
(10)
Cross-Over Studies
(8)
Diabetes Mellitus
(8)
Diabetes Mellitus, Type 2 - Blood
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles

Biosimilar insulins: guidance for data interpretation by clinicians and users

Safety, efficacy and weight effect of two 11β-HSD1 inhibitors in metformin-treated patients with type 2 diabetes

Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus

novel insulin formulation with a more rapid onset of action

Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction

Glucodynamics of long-acting basal insulin peglispro compared with insulin glargine at steady state in patients with type 1 diabetes: substudy of a randomized crossover trial

Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin

Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes

Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes

Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus

Short-term metabolic effects of prednisone administration in healthy subjects

Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes

Exploring the insulin secretory properties of the PGD(2)-GPR44/DP2 axis in vitro and in a randomized phase-1 trial of type 2 diabetes patients

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes

Availability of Inhaled Insulin Promotes Greater Perceived Acceptance of Insulin Therapy in Patients With Type 2 Diabetes

Evaluation of performance of a continuous glucose measurement device in subjects with type 1 and type 2 diabetes by means of a glucose clamp (hypoglycemia performance feasibility)

Safety, efficacy and weight effect of two 11[beta]-HSD1 inhibitors in metformin-treated patients with type 2 diabetes

alpha-Lipoic acid in NIDDM patients with cardiac autonomic neuropathy

Another Meaningful End Point for Nighttime Intensivist Coverage

Pharmacokinetic and Pharmacodynamic Responses of Insulin Degludec in African American, White, and Hispanic/Latino Patients With Type 2 Diabetes Mellitus

Antisense Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes

Rapid Glycometabolic Improvement in Type 2 Diabetic (T2D) Patients with an ADA Isocaloric Diet Over a 22-Day Confinement in a Phase I Research Unit

Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes

Suchergebnisse filtern